Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretrovir. Geneva: World Health Organization; 2018.
2. Couturier J, Lewis DE. HIV persistence in adipose tissue reservoirs. Curr HIV/AIDS Rep. 2018;15:60–71. https://doi.org/10.1007/s11904-018-0378-z.
3. Labarthe L, Gelé T, Gouget H, Benzemrane M, Le CP, Legrand N, et al. Pharmacokinetics and tissue distribution of tenofovir, emtricitabine and dolutegravir in mice. J Antimicrob Chemother. 2022;77(4):1094–101.
4. Castellino S, Moss L, Wagner D, Borland J, Song I, Chen S, et al. Metabolism, excretion, and mass balance of the hiv-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother. 2013;57:3536–46. https://doi.org/10.1128/AAC.00292-13.
5. Broadley KJ. The vascular effects of trace amines and amphetamines. Pharmacol Ther. 2010;125:363–75. https://doi.org/10.1016/j.pharmthera.2009.11.005.